Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.015
Yichen Li, Juanjuan Liu, Hong-xiang Guo
Endotoxemia is a pathophysiological manifestation caused by the release of large amounts of endotoxin from bacteria in the blood or in the lesion. It can cause multiple organ failure, irreversible shock, and even death. The mortality rate of endotoxemiaIt is high. Bacterial endotoxin is the main cause of endotoxemia. At present, there is no safe and effective drug to treat endotoxemia in clinic. Research shows that blood purification can effectively reduce endotoxin level in the blood, then achieve the goal of treatment of endotoxemia. In this paper, the pathogenesis of endotoxemia, the development of hemoperfusion therapy technology, the mechanism and research status of endotoxin adsorption by different hemoperfusion resin were discussed, and the performance and safety requirements of hemoperfusion adsorbent materials for endotoxemia treatment were studied, so as to provide theoretical support for the synthesis of new hemoperfusion adsorption materials for the treatment of endotoxemia. Key words: Hemoperfusion; Endotoxemia; Asorption mechanism
{"title":"Mechanism and research status of hemoperfusion in endotoxemia treatment","authors":"Yichen Li, Juanjuan Liu, Hong-xiang Guo","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.015","url":null,"abstract":"Endotoxemia is a pathophysiological manifestation caused by the release of large amounts of endotoxin from bacteria in the blood or in the lesion. It can cause multiple organ failure, irreversible shock, and even death. The mortality rate of endotoxemiaIt is high. Bacterial endotoxin is the main cause of endotoxemia. At present, there is no safe and effective drug to treat endotoxemia in clinic. Research shows that blood purification can effectively reduce endotoxin level in the blood, then achieve the goal of treatment of endotoxemia. In this paper, the pathogenesis of endotoxemia, the development of hemoperfusion therapy technology, the mechanism and research status of endotoxin adsorption by different hemoperfusion resin were discussed, and the performance and safety requirements of hemoperfusion adsorbent materials for endotoxemia treatment were studied, so as to provide theoretical support for the synthesis of new hemoperfusion adsorption materials for the treatment of endotoxemia. \u0000 \u0000 \u0000Key words: \u0000Hemoperfusion; Endotoxemia; Asorption mechanism","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"441-445"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47167602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.007
Wei Li
Objective To analyze the association between hexokinase 2 (HK2) gene expression and clinical pathological characteristics in renal clear cell carcinoma using database and bioinformatics methods. Methods Oncomine database was used to analyze the most significant differentially expressed genes between renal clear cell carcinoma and non-kidney tissue. The expression levels of mRNA and protein were detected by GPEIA and The Human Protein Atlas database. Correlation of HK2 expression level between clinicopathological features and prognosis of renal clear cell carcinoma was analyzed using LinkedOmics and KM-plotter databases, respectively. The STRING database was used to predict the potential protein interaction mechanism. Results The most significant difference protein in renal clear cell carcinoma, i.e. HK2, was found, which was highly expressed in renal clear cell carcinoma tissues, and positively correlated with pathological stage, T stage and N stage of renal cell carcinoma (all P<0.05). The overall survival rate of the renal clear cell carcinoma patients with high expression of HK2 was significantly lower than that of the patients with low expression (P<0.05). Conclusions High expression of HK2 gene may be associated with pathological staging, high T stage, high N stage, and poor prognosis of renal clear cell carcinoma. Key words: Renal clear cell carcinoma; Hexokinase 2; Bioinformatics
目的应用数据库和生物信息学方法分析肾透明细胞癌己糖激酶2 (HK2)基因表达与临床病理特征的关系。方法利用Oncomine数据库分析肾透明细胞癌与非肾组织间最显著差异表达基因。通过GPEIA和The Human protein Atlas数据库检测mRNA和蛋白的表达水平。应用LinkedOmics和KM-plotter数据库分别分析HK2表达水平与肾透明细胞癌临床病理特征和预后的相关性。利用STRING数据库预测潜在的蛋白相互作用机制。结果肾透明细胞癌组织中差异最显著的蛋白为HK2，该蛋白在肾透明细胞癌组织中高表达，与肾透明细胞癌病理分期、T分期、N分期呈正相关(均P<0.05)。高表达HK2的肾透明细胞癌患者的总生存率显著低于低表达患者(P<0.05)。结论HK2基因的高表达可能与肾透明细胞癌的病理分期、高T分期、高N分期及预后不良有关。关键词:肾透明细胞癌;己糖激酶2;生物信息学
{"title":"Discovery of the expression of HK2 gene in clear cell carcinoma of the kidney and its clinical significance based on database analysis","authors":"Wei Li","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.007","url":null,"abstract":"Objective \u0000To analyze the association between hexokinase 2 (HK2) gene expression and clinical pathological characteristics in renal clear cell carcinoma using database and bioinformatics methods. \u0000 \u0000 \u0000Methods \u0000Oncomine database was used to analyze the most significant differentially expressed genes between renal clear cell carcinoma and non-kidney tissue. The expression levels of mRNA and protein were detected by GPEIA and The Human Protein Atlas database. Correlation of HK2 expression level between clinicopathological features and prognosis of renal clear cell carcinoma was analyzed using LinkedOmics and KM-plotter databases, respectively. The STRING database was used to predict the potential protein interaction mechanism. \u0000 \u0000 \u0000Results \u0000The most significant difference protein in renal clear cell carcinoma, i.e. HK2, was found, which was highly expressed in renal clear cell carcinoma tissues, and positively correlated with pathological stage, T stage and N stage of renal cell carcinoma (all P<0.05). The overall survival rate of the renal clear cell carcinoma patients with high expression of HK2 was significantly lower than that of the patients with low expression (P<0.05). \u0000 \u0000 \u0000Conclusions \u0000High expression of HK2 gene may be associated with pathological staging, high T stage, high N stage, and poor prognosis of renal clear cell carcinoma. \u0000 \u0000 \u0000Key words: \u0000Renal clear cell carcinoma; Hexokinase 2; Bioinformatics","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"398-403"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42882746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.009
Shuo Wang, Chunrong Xu, Y. Xiang, Dangguo Shao, Lijun Liu
Objective To study a maximum between-cluster variance based on differential search algorithm, and to select the multi-threshold for effectively segmentation of brain magnetic resonance images. Methods The brain extraction tool(BET) algorithm was used to remove the non-brain tissue part of the original magnetic resonance image. The best-fit with coalescing(BFC) algorithm was used to remove the intensity non-uniformity. The differential search algorithm was used to optimize the maximum between-cluster variance of the image to find the optimal threshold for multi-threshold segmentation of the magnetic resonance image. The method was validated using simulated magnetic resonance(MR) brain image data provided by BrainWeb. Results For MR images with different noise levels and intensity inhomogeneities, the proposed method was better than FSL, SPM and Brainsuite methods. Conclusions The maximum between-cluster variance based on differential search algorithm has better segmentation accuracy and robustness, especially for cerebrospinal fluid. Key words: Magnetic resonance imaging; Differential search; Image segmentation; Multi threshold; OTSU
目的研究基于差分搜索的最大聚类方差算法，选择多阈值对脑磁共振图像进行有效分割。方法采用脑提取工具(brain extraction tool, BET)算法去除原始磁共振图像中的非脑组织部分。采用最佳拟合合并(best fit with coalescing, BFC)算法去除图像的强度不均匀性。采用差分搜索算法对图像的最大聚类间方差进行优化，找到对磁共振图像进行多阈值分割的最佳阈值。使用BrainWeb提供的模拟磁共振(MR)脑图像数据对该方法进行了验证。结果对于不同噪声水平和强度不均匀性的MR图像，该方法优于FSL、SPM和Brainsuite方法。结论基于最大聚类间方差的差分搜索算法具有较好的分割精度和鲁棒性，尤其对脑脊液具有较好的分割效果。关键词:磁共振成像;微分搜索;图像分割;多阈值;大津
{"title":"Brain tissue segmentation method based on maximum between-cluster variance optimized by the difference search algorithm","authors":"Shuo Wang, Chunrong Xu, Y. Xiang, Dangguo Shao, Lijun Liu","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.009","url":null,"abstract":"Objective \u0000To study a maximum between-cluster variance based on differential search algorithm, and to select the multi-threshold for effectively segmentation of brain magnetic resonance images. \u0000 \u0000 \u0000Methods \u0000The brain extraction tool(BET) algorithm was used to remove the non-brain tissue part of the original magnetic resonance image. The best-fit with coalescing(BFC) algorithm was used to remove the intensity non-uniformity. The differential search algorithm was used to optimize the maximum between-cluster variance of the image to find the optimal threshold for multi-threshold segmentation of the magnetic resonance image. The method was validated using simulated magnetic resonance(MR) brain image data provided by BrainWeb. \u0000 \u0000 \u0000Results \u0000For MR images with different noise levels and intensity inhomogeneities, the proposed method was better than FSL, SPM and Brainsuite methods. \u0000 \u0000 \u0000Conclusions \u0000The maximum between-cluster variance based on differential search algorithm has better segmentation accuracy and robustness, especially for cerebrospinal fluid. \u0000 \u0000 \u0000Key words: \u0000Magnetic resonance imaging; Differential search; Image segmentation; Multi threshold; OTSU","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"409-413"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44951079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.003
Wenlong Yang, S. Zhang, Guozhong Zhang, Yuanfan Xiao
Objective To explored the bio-compatibility and cartilage regeneration of the rabbits genipin cross-linked decellularized scaffold, to provide experimental and theoretical support for the clinical application of genipin cross-linked decellularized scaffold. Methods Detergent-enzyme method was used to prepare decellularized tracheal scaffolds. Cellular content of native trachea and decellularized trachea were compared by 4′, 6-diamidino-2-phenylindole(DAPI) staining. Masson trichrome staining was used to compare the histological structure of the progenitor tube, decellularized trachea, and genipin cross-linked decellularized trachea. Nine adult New Zealand white rabbits were randomly divided into autologous tracheal transplantation group (negative control group), allogeneic tracheal transplantation group (positive control group), and genipin cross-linked decellularized tracheal transplantation group (experimental group). Autologous bone marrow mesenchymal stem cells were implanted on the surface of trachea in each group. The blood cells and type II collagen were detected to compare the inflammatory response and chondrocyte regeneration after tracheal orthotopic transplantation in the three groups. Results After DAPI staining and light microscope observation (×200), the cell content of the acellular 7-cycle trachea [(143.0 ± 71.1) cells/field] was significantly lower than that of the native trachea [(853.5 ± 149.6) cells/field], and the difference was statistically significant (P<0.001). Masson′s trichrome staining showed that the tissue structure of genipin cross-linked decellularized trachea was more complete. Blood cell analysis and type II collagen test results showed that genipin cross-linked decellularized trachea transplanted with bone marrow mesenchymal stem cells after transplantation in situ has little rejection and can be converted into chondrocytes by the action of related growth factors in vivo. Conclusions Genipin cross-linked decellularized tracheal scaffold combined with stem cell transplantation can successfully construct a tracheal in situ replacement model. This study provides a strong support for the research of tissue engineering trachea. Key words: Tissue engineering; Trachea; Transplantation; Genipin cross-linked; Mesenchymal stem cells
{"title":"Genipin cross-linked decellularized scaffold for allogenic transplantation in situ","authors":"Wenlong Yang, S. Zhang, Guozhong Zhang, Yuanfan Xiao","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.003","url":null,"abstract":"Objective \u0000To explored the bio-compatibility and cartilage regeneration of the rabbits genipin cross-linked decellularized scaffold, to provide experimental and theoretical support for the clinical application of genipin cross-linked decellularized scaffold. \u0000 \u0000 \u0000Methods \u0000Detergent-enzyme method was used to prepare decellularized tracheal scaffolds. Cellular content of native trachea and decellularized trachea were compared by 4′, 6-diamidino-2-phenylindole(DAPI) staining. Masson trichrome staining was used to compare the histological structure of the progenitor tube, decellularized trachea, and genipin cross-linked decellularized trachea. Nine adult New Zealand white rabbits were randomly divided into autologous tracheal transplantation group (negative control group), allogeneic tracheal transplantation group (positive control group), and genipin cross-linked decellularized tracheal transplantation group (experimental group). Autologous bone marrow mesenchymal stem cells were implanted on the surface of trachea in each group. The blood cells and type II collagen were detected to compare the inflammatory response and chondrocyte regeneration after tracheal orthotopic transplantation in the three groups. \u0000 \u0000 \u0000Results \u0000After DAPI staining and light microscope observation (×200), the cell content of the acellular 7-cycle trachea [(143.0 ± 71.1) cells/field] was significantly lower than that of the native trachea [(853.5 ± 149.6) cells/field], and the difference was statistically significant (P<0.001). Masson′s trichrome staining showed that the tissue structure of genipin cross-linked decellularized trachea was more complete. Blood cell analysis and type II collagen test results showed that genipin cross-linked decellularized trachea transplanted with bone marrow mesenchymal stem cells after transplantation in situ has little rejection and can be converted into chondrocytes by the action of related growth factors in vivo. \u0000 \u0000 \u0000Conclusions \u0000Genipin cross-linked decellularized tracheal scaffold combined with stem cell transplantation can successfully construct a tracheal in situ replacement model. This study provides a strong support for the research of tissue engineering trachea. \u0000 \u0000 \u0000Key words: \u0000Tissue engineering; Trachea; Transplantation; Genipin cross-linked; Mesenchymal stem cells","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"419 ","pages":"375-382"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41314572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.011
Jing Wu
Long-chain non-coding RNA (LncRNA) has more than 200 nucleotides in length and cannot encode proteins. It has a variety of biological functions. A large number of studies have shown that LncRNA is closely related to the occurrence and development of cancer. Researches at the level of molecular biology have found that LncRNA acts as an important regulatory molecule involved in the whole process of life activities and plays a regulatory role in various diseases and tumors. LincRNA-p21 is a novel LncRNA that acts as a translational inhibitor by targeting mRNA or by directing the chromatin site of a protein-binding partner. LincRNA-p21 is closely related to a variety of tumors and exerts its biological functions of carcinogenesis or tumor suppression through different pathways. In this paper, the research progress of the tumor-associated gene LincRNA-p21 was reviews Key words: Non-coding RNA; Long intergenic non-coding RNA; LncRNA-p21; Tumor
{"title":"Research progress of LincRNA-p21 in tumors","authors":"Jing Wu","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.011","url":null,"abstract":"Long-chain non-coding RNA (LncRNA) has more than 200 nucleotides in length and cannot encode proteins. It has a variety of biological functions. A large number of studies have shown that LncRNA is closely related to the occurrence and development of cancer. Researches at the level of molecular biology have found that LncRNA acts as an important regulatory molecule involved in the whole process of life activities and plays a regulatory role in various diseases and tumors. LincRNA-p21 is a novel LncRNA that acts as a translational inhibitor by targeting mRNA or by directing the chromatin site of a protein-binding partner. LincRNA-p21 is closely related to a variety of tumors and exerts its biological functions of carcinogenesis or tumor suppression through different pathways. In this paper, the research progress of the tumor-associated gene LincRNA-p21 was reviews \u0000 \u0000 \u0000Key words: \u0000Non-coding RNA; Long intergenic non-coding RNA; LncRNA-p21; Tumor","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"419-424"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49088328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although the combination of surgery, radiotherapy and chemotherapy is the main methods of cancer treatment, it still fails to solve certain tumors, especially metastatic tumors. With the in-depth study of tumorigenesis and development mechanism, and the exploration and clinical application of tumor immunotherapy, the survival period of patients with malignant tumors has been significantly prolonged. Tumor immunotherapy has become an effective anti-tumor method by activating the body′s own immune system to achieve tumor suppression. The combination of chemotherapy and immunotherapy has a significant effect and has become a feasible solution for cancer treatment. The rationally designed nanomedicines can effectively combine chemical drugs and immunological preparations, and have become an effective delivery carrier basis and treatment means for clinically targeting tumor tissues, synergistic immune mechanisms to kill tumor cells, and treating tumors. In this paper, the types of multifunctional nanomedicines used in chemotherapy and various immunotherapies in recent years and their advantages in cancer therapy were reviewed. Key words: Nanomedicine; Cancer therapy; Immunotherapy; Chemotherapy; Combined treatment
{"title":"Research progress in multifunctional nanomedicine for the combination of tumor chemotherapy and immunotherapy","authors":"Shurui Ma, Hangtian Zhang, Hongyang Chen, Q. He, Xing-long Li, Danhui Hu, Quanxin Li","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.012","url":null,"abstract":"Although the combination of surgery, radiotherapy and chemotherapy is the main methods of cancer treatment, it still fails to solve certain tumors, especially metastatic tumors. With the in-depth study of tumorigenesis and development mechanism, and the exploration and clinical application of tumor immunotherapy, the survival period of patients with malignant tumors has been significantly prolonged. Tumor immunotherapy has become an effective anti-tumor method by activating the body′s own immune system to achieve tumor suppression. The combination of chemotherapy and immunotherapy has a significant effect and has become a feasible solution for cancer treatment. The rationally designed nanomedicines can effectively combine chemical drugs and immunological preparations, and have become an effective delivery carrier basis and treatment means for clinically targeting tumor tissues, synergistic immune mechanisms to kill tumor cells, and treating tumors. In this paper, the types of multifunctional nanomedicines used in chemotherapy and various immunotherapies in recent years and their advantages in cancer therapy were reviewed. \u0000 \u0000 \u0000Key words: \u0000Nanomedicine; Cancer therapy; Immunotherapy; Chemotherapy; Combined treatment","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"425-429"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42772657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.001
B. Chao, Lei Cao, W. Tu
Stroke is one of the main causes of mortality, long-term physical and cognitive impairment in China. In order to meet the challenge, Stroke Prevention and Treatment Project of the National Health Commission(SPTPC) was established in April 2011 in the Ministry of Health. In 2016, SPTPC issued a work plan of stroke center hospital. In order to shorten the time of pre-hospital, the SPTPC established the stroke center network, stroke map and stroke green channel to create "the three 1-hour gold rescue circle" to form a hierarchical stroke diagnosis and treatment system. The current construction of the Chinese Stroke Center is divided into two levels and four layers. As of December 31, 2018, SPTPC has certified a total of 310 advanced stroke centers, including 30 demonstration advanced stroke centers and 280 advanced stroke centers, and 127 stroke prevention centers, including 85 demonstration stroke prevention centers and 42 stroke prevention centers. The median time from admission to intravenous thrombolysis (DNT) at the advanced stroke center was decreased by 13.2% (53 min vs. 46 min) in the fourth quarter of 2018 as compared with that in the first quarter of 2017.The national thrombolytic rate of acute ischemic stroke was increased 3.24 times (1.78% vs. 0.42%) in 2017 compared that in 2010. In the next step, SPTPC will vigorously promote the construction of stroke centers and graded diagnosis and treatment mechanisms, consolidate quality control and standardization, increase the scope of influence of mobile stroke and remote diagnosis and treatment, and further improve the construction of stroke center systems with Chinese characteristics. Key words: Stroke; Stroke prevention and control system; Stroke center; China
{"title":"Construction of national stroke center network system","authors":"B. Chao, Lei Cao, W. Tu","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.001","url":null,"abstract":"Stroke is one of the main causes of mortality, long-term physical and cognitive impairment in China. In order to meet the challenge, Stroke Prevention and Treatment Project of the National Health Commission(SPTPC) was established in April 2011 in the Ministry of Health. In 2016, SPTPC issued a work plan of stroke center hospital. In order to shorten the time of pre-hospital, the SPTPC established the stroke center network, stroke map and stroke green channel to create \"the three 1-hour gold rescue circle\" to form a hierarchical stroke diagnosis and treatment system. The current construction of the Chinese Stroke Center is divided into two levels and four layers. As of December 31, 2018, SPTPC has certified a total of 310 advanced stroke centers, including 30 demonstration advanced stroke centers and 280 advanced stroke centers, and 127 stroke prevention centers, including 85 demonstration stroke prevention centers and 42 stroke prevention centers. The median time from admission to intravenous thrombolysis (DNT) at the advanced stroke center was decreased by 13.2% (53 min vs. 46 min) in the fourth quarter of 2018 as compared with that in the first quarter of 2017.The national thrombolytic rate of acute ischemic stroke was increased 3.24 times (1.78% vs. 0.42%) in 2017 compared that in 2010. In the next step, SPTPC will vigorously promote the construction of stroke centers and graded diagnosis and treatment mechanisms, consolidate quality control and standardization, increase the scope of influence of mobile stroke and remote diagnosis and treatment, and further improve the construction of stroke center systems with Chinese characteristics. \u0000 \u0000 \u0000Key words: \u0000Stroke; Stroke prevention and control system; Stroke center; China","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"363-366"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49562328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the enhancement effect of Xinjiang wild Artemisia rupestris L. crude polysaccharides (WARCP) as an adjuvant on ovalbumin (OVA) vaccine in mice immunized intramuscularly. Methods ICR mice were randomly divided into 6 groups (5 per group), including 9 g/L NaCl group (blank control), OVA group (10 μg OVA), low dose WARCP/OVA group (OVA+50 μg WARCP), medium dose WARCP/OVA group (OVA+200 μg WARCP), high dose WARCP/OVA group (OVA+400 μg WARCP), and aluminum adjuvant (Alum)/OVA group (positive control group, OVA+100 μg Alum). ICR mice were immunized intramuscularly and weighted. The OVA-specific antibodies and subtypes in serum were detected by enzyme linked immunosorbent assay (ELISA). T cells subsets from spleen and lymph nodes were detected by flow cytometry. Results The medium-dose WARCP/OVA group enhanced IgG and IgG1 levels and increased early antibody levels (all P 0.05). The low-dose WARCP/OVA group enhanced the percentage of CD4+ T cells in spleen and CD4+ T, CD8+ T, CD4+CD44+ T cells in lymph nodes (all P<0.05). The medium dose WARCP/OVA group and the high dose WARCP/OVA group enhanced the CD4+ T, CD8+ T, CD4+CD44+ T, CD8+CD44+ T cells in spleen and CD8+CD44+ T cell in lymph nodes (all P<0.05). Conclusions Plant-derived WARCP as an OVA protein vaccine adjuvant can enhance cellular immunity and humoral immunity, and it is safe and reliable. The results in this study provide a theoretical basis for the popularization and application of WARCP. Key words: Wild Artemisia rupestris L.; Crude polysaccharides; Intramuscular immunization; Adjuvant
{"title":"Immunomodulatory activity of wild Artemisia rupestris L. crude polysaccharide as an adjuvant","authors":"Quanxiao Li, Xueli Ba, Shuangshuang Feng, Ya-Li Tan, Bing Zhao, Xiaolong Luo","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.002","url":null,"abstract":"Objective \u0000To investigate the enhancement effect of Xinjiang wild Artemisia rupestris L. crude polysaccharides (WARCP) as an adjuvant on ovalbumin (OVA) vaccine in mice immunized intramuscularly. \u0000 \u0000 \u0000Methods \u0000ICR mice were randomly divided into 6 groups (5 per group), including 9 g/L NaCl group (blank control), OVA group (10 μg OVA), low dose WARCP/OVA group (OVA+50 μg WARCP), medium dose WARCP/OVA group (OVA+200 μg WARCP), high dose WARCP/OVA group (OVA+400 μg WARCP), and aluminum adjuvant (Alum)/OVA group (positive control group, OVA+100 μg Alum). ICR mice were immunized intramuscularly and weighted. The OVA-specific antibodies and subtypes in serum were detected by enzyme linked immunosorbent assay (ELISA). T cells subsets from spleen and lymph nodes were detected by flow cytometry. \u0000 \u0000 \u0000Results \u0000The medium-dose WARCP/OVA group enhanced IgG and IgG1 levels and increased early antibody levels (all P 0.05). The low-dose WARCP/OVA group enhanced the percentage of CD4+ T cells in spleen and CD4+ T, CD8+ T, CD4+CD44+ T cells in lymph nodes (all P<0.05). The medium dose WARCP/OVA group and the high dose WARCP/OVA group enhanced the CD4+ T, CD8+ T, CD4+CD44+ T, CD8+CD44+ T cells in spleen and CD8+CD44+ T cell in lymph nodes (all P<0.05). \u0000 \u0000 \u0000Conclusions \u0000Plant-derived WARCP as an OVA protein vaccine adjuvant can enhance cellular immunity and humoral immunity, and it is safe and reliable. The results in this study provide a theoretical basis for the popularization and application of WARCP. \u0000 \u0000 \u0000Key words: \u0000Wild Artemisia rupestris L.; Crude polysaccharides; Intramuscular immunization; Adjuvant","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"367-374"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47405880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.013
Qian Li, Wenlu Zhang, Hong Wang, Yan Wang
Nitric oxide is a messenger molecule in the body, which is widely distributed in various tissues of living organisms and participates in regulating the physiological activities of cells. Inhalation of low concentrations of NO can selectively relax the pulmonary blood vessels, which can achieve good results and has been applied in clinical respiratory emergency treatment such as pulmonary hypertension, neonatal hypoxic respiratory failure, acute respiratory distress syndrome (ARDS), etc. At present, in addition to the clinical use of chemical methods to produce NO gas (storage in cylinders), NO can also be generated by discharge. Among them, the pulsed arc discharge can realize the preparation of NO at any time and solve the problems of decompression and storage of conventional NO gas supply. In this paper, the clinical application of NO, discharge technology, and removal methods of nitrogen dioxide (NO2) were reviewed. Key words: Nitric oxide; Pulse discharge; Plasma; Preparation; Catalyticreduction
{"title":"Research progress of medical nitric oxide production technology","authors":"Qian Li, Wenlu Zhang, Hong Wang, Yan Wang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.013","url":null,"abstract":"Nitric oxide is a messenger molecule in the body, which is widely distributed in various tissues of living organisms and participates in regulating the physiological activities of cells. Inhalation of low concentrations of NO can selectively relax the pulmonary blood vessels, which can achieve good results and has been applied in clinical respiratory emergency treatment such as pulmonary hypertension, neonatal hypoxic respiratory failure, acute respiratory distress syndrome (ARDS), etc. At present, in addition to the clinical use of chemical methods to produce NO gas (storage in cylinders), NO can also be generated by discharge. Among them, the pulsed arc discharge can realize the preparation of NO at any time and solve the problems of decompression and storage of conventional NO gas supply. In this paper, the clinical application of NO, discharge technology, and removal methods of nitrogen dioxide (NO2) were reviewed. \u0000 \u0000 \u0000Key words: \u0000Nitric oxide; Pulse discharge; Plasma; Preparation; Catalyticreduction","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"430-435"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42675262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1673-4181.2019.05.014
Zhijun Li, Hua-feng Zhang
The interface of ligaments, tendons, and bones are susceptible to damage, often fail to heal themselves, and even cannot achieve a good prognosis after surgery. Interface tissue engineering is a comprehensive strategy to functionally connect soft and hard tissues to regenerate original anatomical functions and structures, thereby improving clinical efficacy. In this paper, the interface tissue engineering and composite tissue regeneration in soft tissue healing were systematically reviewed. The recent advances in interface engineering were summarized, based on the treatment of structural damage from two common soft tissue-bone connections (ligamentous bone connections, tendon bone connections), from the development of single tissue to composite tissue structures. The latest interface tissue engineering innovation structure design and potential clinical applications in recent years were reviewed. For future research, in-depth research on the mechanisms of interface development, regeneration, and internal environment balance, structure-function relationships, and biological processes that drive interface development, regeneration, and internal environment balance are still necessary. The innovative studies on interface tissue engineering have promoted the significance of the integration of tissue engineering and clinical, and the construction of complex tissues, so that it has broader significance for the future regeneration of total joints. Key words: Biomaterial; Tendon; Ligament; Tissue engineering; Soft and hard tissue repair
{"title":"Research progress in bone interface tissue engineering for ligament and tendon injury","authors":"Zhijun Li, Hua-feng Zhang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.05.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.05.014","url":null,"abstract":"The interface of ligaments, tendons, and bones are susceptible to damage, often fail to heal themselves, and even cannot achieve a good prognosis after surgery. Interface tissue engineering is a comprehensive strategy to functionally connect soft and hard tissues to regenerate original anatomical functions and structures, thereby improving clinical efficacy. In this paper, the interface tissue engineering and composite tissue regeneration in soft tissue healing were systematically reviewed. The recent advances in interface engineering were summarized, based on the treatment of structural damage from two common soft tissue-bone connections (ligamentous bone connections, tendon bone connections), from the development of single tissue to composite tissue structures. The latest interface tissue engineering innovation structure design and potential clinical applications in recent years were reviewed. For future research, in-depth research on the mechanisms of interface development, regeneration, and internal environment balance, structure-function relationships, and biological processes that drive interface development, regeneration, and internal environment balance are still necessary. The innovative studies on interface tissue engineering have promoted the significance of the integration of tissue engineering and clinical, and the construction of complex tissues, so that it has broader significance for the future regeneration of total joints. \u0000 \u0000 \u0000Key words: \u0000Biomaterial; Tendon; Ligament; Tissue engineering; Soft and hard tissue repair","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"436-440"},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47488445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：